Navigation Links
Possible predictive biomarker for patients who may respond to autophagy inhibitors

WASHINGTON, DC Autophagy, the process by which cells that are starved for food resort to chewing up their own damaged proteins and membranes and recycling them into fuel, has emerged as a key pathway that cancer cells use to survive in the face of assault by chemotherapy and radiation. Using drugs to shut down that survival mechanism shows great promise, especially when combined with targeted agents and standard chemotherapies, but until recently, it has been unclear which patients' cancers would respond to that combination therapy.

A team led by researchers from the Perelman School of Medicine at the University of Pennsylvania will present findings (Presentation #1679A) during the AACR Annual Meeting 2013 showing that colon cancer and lung cancer cell lines which expressed a gene known as helicase-like transcription factor (HLTF) tended to be impervious to the effects of the autophagy inhibition drug hydroxycholoroquine (HCQ), a drug originally used as an antimalarial agent. Cells where HLTF is silent, however, appeared to be sensitive to HCQ, which led the team to test HLTF expression in a group of colon cancer patients treated with two chemotherapies (the FOLFOX regimen plus bevacizumab) and HCQ. They found that low expression of HLTF predicted those who would respond to the combination therapy.

Since previous studies have shown that HLTF gene silencing is common in 20 to 40 percent of many epithelial cancers, the Penn team is hopeful their findings could lead to the development of a predictive biomarker to identify patients with other cancers who are most likely to respond to drug therapies involving autophagy inhibitors.

The study will be presented by Ravi Amaravadi, MD, in the Autophagy and Cell Death poster session, Hall A-C, Poster Section 23, at the at the Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, DC 20001, from 1 p.m. to 5 p.m. ET on Monday, April 8, 2013.


Contact: Holly Auer
University of Pennsylvania School of Medicine

Page: 1

Related medicine news :

1. Causes of migraines nearly impossible to determine
2. Early COPD diagnosis possible with nuclear medicine
3. Mesothelioma Victims Center Now Urges Any Retired Industrial or Manufacturing Worker Diagnosed With Mesothelioma To Call Them For The Names Of The Best Possible Law Firms
4. Lung Cancer Asbestos Victims Center Now Urges All Industrial Workers Who Had Exposure to Asbestos at Work and Now Have Lung Cancer to Call Them About Possible Compensation
5. Lung Cancer Asbestos Victims Center Now Urges Nonsmoker US Navy Veterans Who Have Any Type Of Lung Cancer To Call them About Possible Compensation
6. Mesothelioma Victims Center Now Urges All Diagnosed Victims Of Mesothelioma To Call Them Immediately For The Names Of The Best Possible Mesothelioma Law Firms
7. Lung Cancer Asbestos Victims Center Urges US Navy Veterans Stricken With Any Type Of Lung Cancer If They Were Exposed In Asbestos - Possible Significant Compensation
8. Los Angeles Periodontist, Dr. Markzar, is Now Informing Patients about the Possible Connection between Gum Disease and Cardiovascular Disease
9. Lung Cancer Asbestos Victims Center Urges Nonsmokers Now Diagnosed With Lung Cancer To Call Them If They Were Exposed To Asbestos At Work-Possible Financial Compensation
10. Lung Cancer Asbestos Victims Center Now Urges US Navy Veterans Who Now Have Lung Cancer And Were Exposed To Asbestos To Call Them About Possible Financial Compensation
11. Mesothelioma Victims Center Now Urges All Victims Of Mesothelioma To Call Them About Financial Compensation And For The Names Of The Best Possible Mesothelioma Law Firms
Post Your Comments:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: